logo
Managing PoTS: Tips for Living with the Chronic Illness Affecting Millions

Managing PoTS: Tips for Living with the Chronic Illness Affecting Millions

Newsweek11-05-2025

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Imagine standing up and your heart suddenly races as if you've sprinted a mile—except you haven't budged. For millions of Americans with Postural Orthostatic Tachycardia Syndrome (PoTS), this dizzying, exhausting reality is their daily norm.
Though not fatal, PoTS profoundly disrupts everyday life, causing a spectrum of symptoms—dizziness, near‑fainting, brain fog, palpitations, fatigue, tremors, chest discomfort, headaches, nausea and gastrointestinal distress.
Recent data suggest PoTS is on the rise. "PoTS can be triggered by SARS‑CoV‑2 infection as part of long COVID," said Dr. Svetlana Blitshteyn, professor of neurology at the University at Buffalo. A 2025 study in The American Journal of Medicine found that nearly 80 percent of long‑COVID patients met the diagnostic criteria for PoTS.
"Prior to the pandemic, at least 3 to 5 million people had PoTS, which has likely doubled after the pandemic," Blitshteyn told Newsweek.
"We still don't know exactly how many Americans currently have PoTS, but it is estimated that millions more Americans are now suffering from this disease," added Dr. Brit Adler, a professor of medicine in the division of rheumatology at Johns Hopkins University.
File photo: a doctor checks a patient's heart rate and blood pressure in a clinic.
File photo: a doctor checks a patient's heart rate and blood pressure in a clinic.
Klaus Rose/dpa via AP
What Is PoTS?
PoTS is described as an abnormality in the functioning of the autonomic nervous system, the system controlling breathing, gut function, heart rate, blood pressure and many other bodily functions.
It can also be linked to problems like "low blood volume, vascular dysfunction, or other mechanisms," Adler said, adding that those with hypermobility syndromes like Ehlers-Danlos Syndrome often had the condition as well.
PoTS comes as a result of the autonomic nervous system's "adjustment to being upright not functioning properly," Professor Lesley Kavi, the chairperson of the U.K.-based charity organization PoTS UK, told Newsweek.
As many basic tasks in the day require postural changes and standing, a person with PoTS is constantly being put under strain as they navigate simple tasks. Symptoms tend to lessen when a patient is horizontal, but it can sometimes take a long time for symptoms to ease off once flared.
Things like heat, prolonged standing, dehydration, stress, intensive exercise, viruses, infections, and menstruation can all worsen PoTS symptoms.
Kavi said that major surgery, injuries such as concussion, and exposure to a traumatic event can trigger an onset of PoTS, but she added that there isn't enough data and research yet to be able to determine precisely what mechanisms are going wrong within the body.
Dr. Zachary Spiritos, a specialist in gastroenterology and hepatology at North Carolina's UNC Health, told Newsweek: "Many people may be born with a vulnerability, and then something in the environment - often an infection or injury - triggers the onset of symptoms. It's multifactorial, and the exact blend is different for everyone."
How Common Is PoTS?
Prevalence estimates range widely: the Cleveland Clinic cites 1–3 million U.S. cases, while Dysautonomia International reports 3–6 million.
This variability stems largely from under-recognition—most clinicians seldom consider PoTS during evaluation, according to Spiritos. Women account for approximately 80 percent of cases in the U.S., according to Dysautonomia International, likely due to hormonal influences and autoimmune predisposition.
"This is partly because the X chromosome carries many immune-related genes, and women have two copies, which can lead to more robust, but also more error-prone, immune responses," Spiritos said, "[And] we see anecdotal patterns where estrogen can worsen PoTS symptoms, while testosterone may be protective."
What The Experts Recommend For PoTS Patients
Lesley Kavi from PoTS UK said that avoiding symptom triggers can be a good place to start for managing the condition, although this is very individual. For some, this could include avoiding prolonged standing, dehydrating things like the heat, alcohol, and caffeine, she added.
Increasing fluid intake is essential, Kavi said, adding an adult with PoTS should aim to drink between two to three liters of water a day, or more if they exercise or are in a hot environment.
In order to ensure the water stays in your system, increasing sodium intake is also important, Kavi said. Patients are advised to increase their sodium intake to as much as 10,000-12,000 mg per day, but each patient will respond best to a different amount.
Compression clothing, particularly tights or leggings that cover the abdomen, are helpful in boosting blood circulation too, Kavi said. Typically medical grade compression is required of between 20 to 30 mmHg.
"Exercise can be something that helps the most for some people, but the problem with exercise is that it can make others feel really terrible afterwards, even for a day or two," Kavi added.
Starting "low and slow" is always the way to go, Kavi said, adding that it was important to get expert input. The best forms of exercise to start with are horizontal, she added, pointing to exercise bikes, Pilates, rowing machines, and swimming.
Although, it is always best to get professional support, Blitshteyn said. "While there are no cures, there is treatment to help you improve and function better in your life."
It is also important to remember "you're not alone and PoTS is a real, physiologic disorder," Adler said. "Many people go years without a diagnosis and are often told that their symptoms are from anxiety and it is in their head."
Spiritos said it's a good idea to educate yourself, as "understanding the condition is empowering," and recommended listening to the POTScast and Bendy Bodies podcasts.
"Ultimately, community and knowledge are power, and with the right tools, you can get better," he added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘It's deadly': The risks of drowning and knowing how to save a life
‘It's deadly': The risks of drowning and knowing how to save a life

Yahoo

timean hour ago

  • Yahoo

‘It's deadly': The risks of drowning and knowing how to save a life

AUSTIN (KXAN) — Local first responders would like people to know what to do in case of a drowning. Austin Public Health said an average of 14 people a year die by drowning in Travis County. Between 2007 and 2016, a total of 140 deaths happened due to unintentional drowning. Half of them were in natural bodies of water — like creeks, lakes or rivers — while 25% of them were in swimming pools. It's why first responders are highlighting the life-saving power of CPR and of an automated external defibrillator, or AED. Captain Trevor Stokes with Travis County Emergency Services District No. 2, otherwise known as the Pflugerville Fire Department, joined KXAN's Will DuPree and Avery Travis to mark CPR and AED Awareness Travis: We know this week is really meant to highlight how people can save lives and be safe out on the water. But let's talk about the issue of drowning. How big of a problem is it in Central Texas? I think a lot of folks growing up in this area learned to swim growing up, or were around swimming pools or the lake. Why might that knowledge maybe make us a little lax about the risks of drowning. Captain Trevor Stokes: So the biggest issue we see is obviously for children, so we recommend putting all the efforts into prevention. Obviously, knowing CPR is a good thing, but at that point, something's already happened. So drowning is silent. It's deadly, and it happens very quickly. So when enjoying water, especially in pools or even an open body of water, like we saw with the incident there at Lake Austin or Town Lake, is having a PFD, wearing a PFD, not just having it near you, but actually wearing it despite your ability to swim. That's a preventative measure. People typically don't drown when they're wearing a PFD. They surface to the top of the water. But more importantly, with kiddos, always having somebody who is watching the children, and then rotating that person regularly. So that's not someone who's reading a book, who's on their phone, they're not distracted, they're watching. Also, if you're in a pool, or if you're in a body of water where visibility is good, having a swimsuit that is not the same color as, say, the bottom of the pool. So that at any moment a kid slips below the surface, you immediately can recognize that. But rotating that person and making sure they understand what their responsibilities are prevents it. Also having likes or any prevention mechanisms so people can't wander off to the water, wander off to the pool, unaided or unassisted or even unwatched, that's a big thing. Will DuPree: Okay, so those are lots of things that people can keep in mind for sure. But if an emergency should happen, obviously calling 911, is important, but so is the importance of someone being a bystander who can jump in and perform CPR. What's the impact that can have on potentially saving someone's life? Stokes: So having knowledge of doing CPR and immediately starting that process while someone is calling 911 — it raises the potential for a save so much higher. CPR is an easy skill to learn. Anyone can do it. You can go to Actually, the Pflugerville Firefighters Association has a free class that goes on monthly. All the information is on our website. There's also a playlist that will help you remember the tempo. But early compressions, early CPR is the best chance to make that a survivable event. Travis: I think we even have that playlist pulled up so we can give it a scroll and let people see some of the songs you guys are actually trying to make this, you know, even entertaining and catchy, something easy for people to remember and learn and kind of put those skills into practice. I saw a Sabrina Carpenter song on there, and so I'll be practicing my CPR to that later today. So we're showing that resource for people and where you can find it. But I do want to ask for someone who the thought of jumping in as a bystander might be really scary, even if they've practiced, even if they've learned the skills. What would you say to folks, who you know that's a scary moment, to jump in and try to do something like that, if you've only ever practiced, maybe on a practice dummy or in a class? Stokes: Well, it's interesting. We're doing Stillwater training right now at Lake Pflugerville. Last year, while we were out there doing that, someone actually started drowning while we were there. So as first responders, we're trained to do that. But even that group had a little hesitation, because they're like, surely, this is not happening right in front of us. So even for trained professionals, it can be stressful. The reality, though, is paying attention, making sure that someone is always watching, especially with kiddos, we can prevent that from ever happening. DuPree: We mentioned a little bit earlier about the device known as an AED, talk to us about what that is and how helpful it can be in an emergency. Stokes: So an AED is an automated external defibrillator, so it's a piece of equipment that has become very popular in public places all across the world. You'll see them in malls. You'll see them in airports. The way they're designed now is you don't need any training in them. As a matter of fact, some of the manufacturers prefer you don't have some training on, say, another brand, and then have to use that from the time you turn it on, it will walk you through every single step. Those that are located near a pool or a body of water — there's very specific directions drawing the person off before you do it. But other than that, it allows the best chance to restart the heart, should it be an electrical issue. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

Business Upturn

time2 hours ago

  • Business Upturn

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. ('Innovent') (HKEX: 01801) today jointly announce that the New Drug Application ('NDA') for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor ('TKI') has been accepted for review by the China National Medical Products Administration ('NMPA'). The NDA is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced renal cell carcinoma. The study has met its primary endpoint of progression free survival ('PFS'), as assessed by blinded independent central review (BICR) according to RECIST 1.1 criteria. The combination also demonstrated improvements in secondary endpoints including objective response rate ('ORR') and duration of response ('DoR'). The safety profile was tolerable and no new safety signals were observed. Data from FRUSICA-2 will be submitted for presentation at an upcoming scientific conference. Additional details may be found at using identifier NCT05522231. 'Kidney cancer continues to pose significant challenges in China, with limited treatment options for patients who fail first-line therapies. Submitting this NDA for the fruquintinib and sintilimab combination for advanced renal cell carcinoma marks an important step in our efforts to address this unmet need,' said Dr Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED. 'We are dedicated to making this combination therapy available to patients with renal cell carcinoma. At the same time, through ongoing research, we remain focused on exploring the full potential of this combination, as well as advancing our broader pipeline across multiple cancer types, to provide more patients with new and effective treatment options.' 'The NDA acceptance of sintilimab and fruquintinib combination represents a significant step toward providing a more effective second line treatment option for patients with advanced renal cell carcinoma in China,' said Dr Hui Zhou, Senior Vice President of Innovent. 'Our PD-1 inhibitor, sintilimab (TYVYT®), has solidified its position as a cornerstone of immuno-oncology (IO) therapy with this NDA as its 10th indication, marking a meaningful milestone in lifecycle management and clinical value optimization.' In December 2024, the combination of fruquintinib and sintilimab received conditional approval from the China NMPA for the treatment of patients with advanced mismatch repair proficient ('pMMR') endometrial cancer who have failed prior systemic therapy and are not candidates for curative surgery or radiation, based on data from the FRUSICA-1 study (NCT03903705). About Kidney Cancer and Renal Cell Carcinoma It is estimated that approximately 435,000 new patients were diagnosed with kidney cancer worldwide in 2022.1 In China, an estimated 74,000 new patients were diagnosed with kidney cancer in 2022.2 Approximately 90% of kidney tumors are renal cell carcinoma. About Fruquintinib Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors ('VEGFR') -1, -2 and -3. VEGFR inhibitors play a pivotal role in inhibiting tumor angiogenesis. Fruquintinib was designed to have enhanced selectivity that limits off-target kinase activity, allowing for drug exposure that achieves sustained target inhibition and flexibility for potential use as part of a combination therapy.3 About Fruquintinib Approvals Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. It is approved for the treatment of patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, and those who have previously received or are not suitable to receive anti-VEGF therapy or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type) in China. It was included in the China National Reimbursement Drug List (NRDL) in January 2020. Since its launch in China, over 100,000 patients with colorectal cancer have been treated with fruquintinib. The combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) has conditional approval in China for the treatment of patients with advanced pMMR endometrial cancer who have failed prior systemic therapy and are not candidates for curative surgery or radiation. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®. Fruquintinib received approval for the treatment of previously treated metastatic colorectal cancer in the US, Europe, Japan and many other countries around the world. The safety and efficacy of fruquintinib for the following investigational uses have not been established and there is no guarantee that it will receive health authority approval or become commercially available in any country for the uses being investigated: About Fruquintinib for Second-line Treatment of Renal Cell Carcinoma Single-agent targeted therapy continues to be one of the primary choices for first-line treatment of advanced renal cell carcinoma in China. Notably, advanced renal cell carcinoma patients who have experienced failure with single-agent targeted therapy previously still indicate an unmet medical need. Results from a proof-of-concept Phase Ib/II study of fruquintinib plus sintilimab were published in Targeted Oncology in January 2025. The combination showed promising efficacy and a tolerable safety profile in this setting. At the data cutoff of October 9, 2024, all 20 enrolled previously treated patients were evaluable for efficacy, with a median follow-up duration of 45.7 months. The confirmed ORR was 60.0% and DCR was 85.0%. Median DoR was 13.9 months and median PFS was 15.9 months. Overall survival ('OS') was not reached, and the 36-month OS rate was 58.3%.4 About Sintilimab Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed and co-commercialized by Innovent and Eli Lilly and Company, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. 5 In China, sintilimab has been approved and included in the updated NRDL for seven indications. The updated NRDL reimbursement scope for TYVYT® (sintilimab injection) includes: For the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy; For the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer lacking EGFR or ALK driver gene mutations; For the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer who progressed after EGFR-TKI therapy; For the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer; For the first-line treatment of unresectable or metastatic hepatocellular carcinoma with no prior systematic treatment; For the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma; For the first-line treatment of unresectable locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Furthermore, sintilimab's eighth indication, in combination with fruquintinib for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, was conditional approved by the NMPA in December 2024. Two NDAs for sintilimab are currently under the NMPA review, including: In combination with ipilimumab as neoadjuvant treatment for resectable MSI-H/dMMR colon cancer is under the NMPA review and has been granted Priority Review designation; In combination with fruquintinib for the treatment of patients with locally advanced or metastatic renal cell carcinoma who failed prior treatment with a TKI. In addition, two clinical studies of sintilimab have met their primary endpoints: Phase 2 study of sintilimab monotherapy as second-line treatment of esophageal squamous cell carcinoma; Phase 3 study of sintilimab monotherapy as second-line treatment for squamous non-small cell lung cancer with disease progression following platinum-based chemotherapy; Statement: Innovent does not recommend the use of any unapproved drug(s)/indication(s). About HUTCHMED HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit or follow us on LinkedIn. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: (1) Innovent does not recommend the use of any unapproved drug (s)/indication(s). (2) Ramucirumab (Cyramza ® ) and Selpercatinib (Retsevmo ® ) and Pirtobrutinib (Jaypirca ® ) were developed by Eli Lilly and Company. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including its expectations regarding the therapeutic potential of the fruquintinib and sintilimab combination for the treatment of patients with advanced renal cell carcinoma and the further clinical development of the fruquintinib and sintilimab combination in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the sufficiency of clinical data to support NDA approval of the fruquintinib and sintilimab combination for the treatment of patients with advanced renal cell carcinoma in China, or other jurisdictions, its potential to gain expeditious approvals from regulatory authorities, the safety profile of fruquintinib, HUTCHMED's ability to fund, implement and complete its further clinical development and commercialization plans for the fruquintinib and sintilimab combination, and the timing of these events. In addition, as certain studies rely on the use of other drug products such as sintilimab as combination therapeutics with fruquintinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on AIM and on The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries +852 2121 8200 / [email protected] Media Enquiries FTI Consulting – +44 20 3727 1030 / [email protected] Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Brunswick – Zhou Yi +852 9783 6894 (Mobile) / [email protected] Panmure Liberum Nominated Advisor and Joint Broker Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500 HSBC Joint Broker Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888 Cavendish Joint Broker Geoff Nash / Nigel Birks +44 20 7220 0500 ____________________ 1 The Global Cancer Observatory, kidney cancer fact sheet. Accessed February 19, 2025. 2 The Global Cancer Observatory, China fact sheet. Accessed February 19, 2025. 3 Sun Q, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther . 2014;15(12):1635-45. doi: 10.4161/15384047.2014.964087. 4 Xu H, et al. Fruquintinib Plus Sintilimab in Patients with Treatment‑Naïve and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial. Targeted Oncolog y. 2025; 20:113–125. 5 Wang J, et al . Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs 2019;11(8): 1443-1451. doi: 10.1080/19420862.2019.1654303. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Presumptive Medicaid eligibility for pregnant Arkansans set to go into effect
Presumptive Medicaid eligibility for pregnant Arkansans set to go into effect

Yahoo

time2 hours ago

  • Yahoo

Presumptive Medicaid eligibility for pregnant Arkansans set to go into effect

Rep. Lee Johnson (left), R-Greenwood, an emergency medicine physician and the Joint Public Health, Welfare and Labor Committee's House chair, asks Department of Human Services officials a question about presumptive Medicaid eligibility for pregnant women on Wednesday, June 4, 2025. At right is Rep. Cameron Cooper, R-Romance. (Screenshot/Arkansas Legislature) Arkansas lawmakers reviewed two rules Wednesday in response to a new law aimed at improving the state's maternal health care landscape for low-income pregnant women. The Joint Public Health, Welfare and Labor Committee spent nearly an hour discussing Arkansas' new policy of presumptive Medicaid eligibility for pregnant women, part of the Healthy Moms, Healthy Babies Act that will go into effect in August. Presumptive eligibility assumes 60 days of Medicaid eligibility and shortens the process of applying for coverage. The policy was among several recommendations to improve the state's maternal health care landscape that a task force convened by Gov. Sarah Huckabee Sanders issued in September 2024. More than half of births in Arkansas are covered by Medicaid, the federal-state health insurance system for low-income Americans. A federal budget bill moving through Congress would make deep cuts to Medicaid spending, reducing the program by $625 billion over 10 years. U.S. House Republicans push through massive tax and spending bill slashing Medicaid Elizabeth Pitman, director of the Division of Medical Services for Arkansas Medicaid, said she anticipates the proposed cuts will affect the state's Medicaid expansion population but not pregnant women on Medicaid. Arkansas has among the nation's highest maternal mortality and infant mortality rates. Rep. Jack Ladyman, R-Jonesboro, said he found this frustrating and considered presumptive Medicaid eligibility 'a very good cornerstone' for improving these statistics. Ladyman and Rep. Lee Johnson, R-Greenwood, asked Pitman and other Department of Human Services officials how they plan to ensure that pregnant Arkansans statewide have the information and resources they need to opt into presumptive Medicaid eligibility if applicable. 'I want to support this rule, but I also want to be realistic in what we expect the outcome of this rule to be,' said Johnson, an emergency medicine physician and the joint committee's House chair. 'If we pass this eligibility category and nobody's applying for it any more often than they're currently applying for Medicaid, then it's not moving the needle.' Pitman said DHS can address Johnson's concerns about access to information in its focus groups with pregnant Arkansans. She also said the agency will work with community health workers, doulas and other local health care providers and community organizations to ensure the option of presumptive Medicaid eligibility is as widely known as possible. Committee outlines recommendations, actions taken to improve maternal health in Arkansas DHS learned during the three-year public health emergency of the COVID-19 pandemic that spreading information about public health resources via social media, digital billboards and doctor's offices successfully reaches the agency's target audience, state Medicaid Director Janet Mann said. In January, Arkansas received a 10-year, $17 million federal grant aimed at improving maternal health outcomes for Medicaid recipients. Applying for the grant was among the maternal health task force's recommendations last year. The grant includes payments to healthcare providers as incentives for improved data-sharing on maternal health outcomes, Pitman said. In response to more questions from Johnson, Pitman said DHS does not have data on whether pregnant Arkansans' first interactions with prenatal health care occur in primary care providers' offices or emergency rooms. Arkansas remains the only state that has taken no action to adopt the federal option of extending postpartum Medicaid coverage from 60 days to 12 months after birth, according to KFF. The maternal health task force did not recommend this policy, and a bill to create it failed in a Senate committee in April after Pitman and Mann expressed DHS' opposition to it. Arkansas Senate committee rejects 12-month postpartum Medicaid coverage The other rule the joint committee reviewed Wednesday was the 'unbundling' of billing rates for labor and delivery, a policy also put forth by the Healthy Moms, Healthy Babies Act. The federal Centers for Medicare and Medicaid Services authorized a 70% increase in Arkansas' maximum reimbursement rate for obstetrical care 'to include prenatal, delivery and postpartum care,' according to the rule. All of these services will be billed separately in all cases, Pitman said. CMS' approval of such a stark increase was 'very unusual,' but Arkansas' shortage of maternal health care providers in rural areas, closure of seven labor and delivery units since 2019 and high maternal and infant mortality rates led the agency to grant DHS' request without question, Pitman said. Higher reimbursement rates should 'improve Medicaid's data collection on utilization of prenatal and postpartum services,' the rule states. 'We're really hopeful that this will give us better data and insight into what is happening in the prenatal care space: when women are going [to the doctor], if it's the first, second or third trimester, who are they seeing and what are their diagnoses,' Pitman said. SUPPORT: YOU MAKE OUR WORK POSSIBLE

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store